JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $31
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price target from $36 to $31.
JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price target from $36 to $31.